Serum N‐Glycan Profiling Predicts Prognosis in Patients Undergoing Hemodialysis

Abstract

Background. The aim of this study is to evaluate the usefulness of serum N-glycan profiling for prognosis in hemodialysis patients. Methods. Serum N-glycan analysis was performed in 100 hemodialysis patients in June 2008 using the glycoblotting method, which allows high-throughput, comprehensive, and quantitative N-glycan analysis. All patients were longitudinally followed up for 5 years. To evaluate the independent predictors for prognosis, patients' background, blood biochemistry, and N-glycans intensity were analyzed using Cox regression multivariate analysis. Selected N-glycans and independent factors were evaluated using the log-rank test with the Kaplan-Meier method to identify the predictive indicators for prognosis. Each patient was categorized according to the number of risk factors to evaluate the predictive potential of the risk criteria for prognosis. Results. In total, 56 N-glycan types were identified in the hemodialysis patients. Cox regression multivariate analysis showed cardiovascular events, body mass index, maximum intima media thickness, and the serum N-glycan intensity of peak number 49 were predictive indicators for overall survival. Risk classification according to the number of independent risk factors revealed significantly poor survival by increasing the number of risk factors. Conclusions. Serum N-glycan profiling may have a potential to predict prognosis in patients undergoing hemodialysis.

Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas

“…N -glycomics was performed as described previously. A 10-μL aliquot of the purified Igs fractions were analyzed using the glycoblotting method [ 11 , 12 , 15 , 33 ] on a Sweetblot instrument (System Instruments, Hachioji, Tokyo, Japan). Then, the resulting benzyloxiamine (BOA)-labelled glycans were detected by matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass spectrometry (Ultraflex 3 TOF/TOF mass spectrometer; Bruker Daltonics, Bremen, Germany) ( Figure A1 a–f).…”

Serum aberrant N-glycan profile as a marker associated with early antibody-mediated rejection in patients receiving a living donor kidney transplant

“…A 10-µL aliquot of whole serum or a Igs fraction purified from whole serum was processed by using the glycoblotting method [8][9][10][11][12][13][14]21] and a controlled automated SweetblotTM instrument (System Instruments, Hachioji, Japan). Then, the resulting BOA-labeled glycans were detected by MALDI-TOF MS (Ultraflex 3 TOF/TOF mass spectrometer; Bruker Daltonics, Bremen, Germany) (Figure 8).…”

Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant

“…Serum N -glycomics was performed as described previously. A 10-μL aliquot of whole serum or a Igs fraction purified from whole serum was processed by using the glycoblotting method [ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 21 ] and a controlled automated SweetblotTM instrument (System Instruments, Hachioji, Japan). Then, the resulting BOA-labeled glycans were detected by MALDI-TOF MS (Ultraflex 3 TOF/TOF mass spectrometer; Bruker Daltonics, Bremen, Germany) ( Figure 8 ).…”

“…Glycosylation has an important role in various biological functions. Recently, our group demonstrated that high-throughput, comprehensive, and quantitative serum N -glycomics was a promising method to screen N -glycan for diagnostic and prognostic markers of several cancers [ 8 , 9 , 10 ] and was a promising predictive tool for patients undergoing hemodialysis [ 11 ]. However, the use of serum N -glycans as a predictive biomarker of ABMR has not yet been tested.…”